Page 120 - Read Online

Giovanis et al. Hepatoma Res 2018;4:10 I http://dx.doi.org/10.20517/2394-5079.2018.21 Page 13 of 13

53. Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J. Independent assessment of lenvatinib plus everolimus in patients with metastatic
renal cell carcinoma. Lancet Oncol 2016;17:e4-5.
54. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Phase 2 study
of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52:512-9.
55. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ,
Lopez C, Ditcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of
patients with unresectable hepatocellular carcinoma: a randomised phase III non-inferiority trial. Lancet 2018;391:1163-73.
56. Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy 2018;38:357-69.
57. Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E.
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol
2017;28:528-34.
58. Abou-Alfa GKMT, Cheng AL. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who
have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018;36:207.
59. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, Meyer T, Kang YK, Yeo W,
Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular
carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
60. NCT02576509. An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With
Advanced Hepatocellular Carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02576509 [Last accessed on 18 Apr 2018].
61. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and safety of transarterial chemoembolization plus
external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomised clinical trial.
JAMA Oncol 2018; doi: 10.1001/jamaoncol.2017.5847.
62. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma
in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis
2011;29:339-63.
63. Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimoto T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S. Early evaluation
of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol 2012;47:343-6.
64. Italian Association for the Study of the Liver (AISF), AISF Expert Panel, AISF Coordinating Committee. Position paper of the Italian
Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis
2013;45:712-23.
65. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines. Ann Oncol 2012;23:vii41-8.
66. Bruix J, Morris Sherman M. AASLD PRACTICE GUIDELINE management of hepatocellular carcinoma: an update. Hepatology
2011;53:1020-2.
67. PR Newswire Release. Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular
Carcinoma Patients Met Overall Survival Endpoint. Available from: https://www.prnewswire.com/news-releases/lilly-
announces-cyramza-ramucirumab-phase-3-reach-2-study-in-second-line-hepatocellular-carcinoma-patients-met-overall-survival-
endpoint-300624113.html [Last accessed on 19 Apr 2018].